OverviewSuggest Edit

Psychemedics Corporation provides testing services for the detection of drug abuse through the analysis of hair samples. The Company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. Psychemedics offers its services to employers for applicant and employee testing, treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use.

TypePublic
Founded1985
HQActon, US
Websitepsychemedics.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Dec 2019)204(-18%)
Revenue (FY, 2019)$37.7 M(-11%)
Share Price (Nov 2020)$4.2 (+3%)
Cybersecurity ratingAMore

Key People/Management at Psychemedics

Raymond C. Kubacki

Raymond C. Kubacki

Chairman, President and C.E.O.
Charles Doucot

Charles Doucot

Executive Vice President
Michael I. Schaffer

Michael I. Schaffer

Vice President-Laboratory Operations
Neil L. Lerner

Neil L. Lerner

Vice President - Finance
Show more

Psychemedics Office Locations

Psychemedics has offices in Acton, Culver City and Dallas
Acton, US (HQ)
289 Great Rd #200
Culver City, US
5832 Uplander Way
Dallas, US
5220 Spring Valley Rd #603
Show all (4)

Psychemedics Financials and Metrics

Psychemedics Revenue

Embed Graph
View revenue for all periods
Psychemedics's revenue was reported to be $37.68 m in FY, 2019
USD

Revenue (Q2, 2020)

3.3m

Gross profit (Q2, 2020)

(252.0k)

Gross profit margin (Q2, 2020), %

(7.6%)

Net income (Q2, 2020)

(2.0m)

EBIT (Q2, 2020)

(3.3m)

Market capitalization (17-Nov-2020)

22.9m

Closing stock price (17-Nov-2020)

4.2

Cash (30-Jun-2020)

3.7m

EV

28.9m
Psychemedics's current market capitalization is $22.9 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

24.1m25.2m26.9m29.2m27.0m39.0m39.7m42.7m37.7m

Revenue growth, %

9%(8%)45%

Cost of goods sold

9.6m11.0m11.5m14.1m14.3m17.5m19.9m22.1m21.2m

Gross profit

14.5m14.3m15.4m15.1m12.7m21.5m19.8m20.6m16.4m
Quarterly
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.6m3.1m4.0m3.6m2.7m3.9m8.2m4.1m7.3m

Accounts Receivable

4.5m4.6m4.4m4.1m3.5m5.8m4.5m4.8m3.8m

Prepaid Expenses

565.5k823.3k769.3k690.0k1.1m1.2m1.1m1.8m

Inventories

1.1m
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Psychemedics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Psychemedics Online and Social Media Presence

Embed Graph

Psychemedics News and Updates

Psychemedics Announces Third Quarter Results

ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020.

Psychemedics Announces Second Quarter Results

ACTON, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020. 

Psychemedics Corporation Announces 4th Quarter and Year-End Results

Declares 94th Consecutive Quarterly Dividend Declares 94th Consecutive Quarterly Dividend

Psychemedics Announces Third Quarter Results and Declares 93rd Consecutive Quarterly Dividend

ACTON, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of November 5, 201…

Psychemedics Corporation Announces New Brazilian Distribution Agreement

ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and with Toxicologia Pardini Ltda., our existing independent distributor in Brazil, formerly known as Psyc…

Psychemedics Announces Second Quarter Results and Declares 92nd Consecutive Quarterly Dividend

ACTON, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August 6, 2019, to …
Show more

Psychemedics Blogs

Rebuilding A Workplace After COVID-19 (Part Three of Three)

The post Rebuilding A Workplace After COVID-19 (Part Three of Three) appeared first on Psychemedics.

Rebuilding A Workplace After COVID-19 (Part Two of Three)

The post Rebuilding A Workplace After COVID-19 (Part Two of Three) appeared first on Psychemedics.

Rebuilding A Workplace After COVID-19 (Part One of Three)

The post Rebuilding A Workplace After COVID-19 (Part One of Three) appeared first on Psychemedics.

Psychemedics Announces a “Vaping Panel” to Detect and Deter the use of Marijuana, CBD and Nicotine

A New and Cost-Effective Tool to Combat the E-cigarette Epidemic Among Youth ACTON, MA, May 5, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced a Vaping Panel to detect the use of Marijuana,…

Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA

A New and Cost-Effective Tool to Detect and Deter Nicotine use ACTON, MA, April 29, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predomi…

Psychemedics Statement on COVID-19 from CEO Ray Kubacki

To our clients, friends, and partners: In this time of uncertainty, we are taking steps to continue delivering the superior levels of service for which Psychemedics has become known. First, as with many of you, our people are our most valued asset and safeguarding their well-being is a top priority.…
Show more

Psychemedics Frequently Asked Questions

  • When was Psychemedics founded?

    Psychemedics was founded in 1985.

  • Who are Psychemedics key executives?

    Psychemedics's key executives are Raymond C. Kubacki, Charles Doucot and Michael I. Schaffer.

  • How many employees does Psychemedics have?

    Psychemedics has 204 employees.

  • What is Psychemedics revenue?

    Latest Psychemedics annual revenue is $37.7 m.

  • What is Psychemedics revenue per employee?

    Latest Psychemedics revenue per employee is $184.7 k.

  • Who are Psychemedics competitors?

    Competitors of Psychemedics include Euroclone Diagnostica, Innovita Biological Technology and NMS Laboratories.

  • Where is Psychemedics headquarters?

    Psychemedics headquarters is located at 289 Great Rd #200, Acton.

  • Where are Psychemedics offices?

    Psychemedics has offices in Acton, Culver City and Dallas.

  • How many offices does Psychemedics have?

    Psychemedics has 4 offices.